Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study.

C. Pinto,V. Mutri,F. Di Fabio,S. Giaquinta,Claudio Ceccarelli,F. L. Rojas Llimpe,P. Di Tullio,Carlo Barone,S. Siena,A. Martoni

Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study.

2010

C. Pinto
V. Mutri
F. Di Fabio
S. Giaquinta
Claudio Ceccarelli
F. L. Rojas Llimpe
P. Di Tullio
Carlo Barone
S. Siena
A. Martoni

4133 Background: The aim of this study was to evaluate the correlation between pathologic biomarkers and objective response (OR), time-to-progression (TTP) and overall survival (OS) in advanced gas...

Keywords:

Cisplatin/Docetaxel
Cetuximab
Cancer
MAPK/ERK pathway
PI3K/AKT/mTOR pathway
Gastroesophageal Junction
Biomarker (medicine)
Oncology
Internal medicine
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations